The Effect of Different Algorithms on Prevalence of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder in Secondary Healthcare Data in Five European Countries: A Contribution from the ConcePTION Project
To assess the effect on prevalence estimates of using different algorithms to identify children with attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in healthcare data. Three algorithms were developed and run on administrative/research data in Finland, France (Haute Garonne), Italy (Emilia Romagna), Norway and Wales: (1) ≥ 1 ADHD or ASD diagnoses recorded in specialist settings, (2) ≥ 2 ADHD or ASD diagnoses recorded in primary care and (3) ≥ 1 prescription for medication to manage ADHD. Prevalence rates per 1000 children for each algorithm were calculated. 3,130,162 children (born 1996-2020) with 29,291,204 years of follow-up were included. ADHD prevalence per 1000 children in specialist settings ranged from 3.9 (Emilia Romagna) to 24.1 (Finland); and was 7.0 in primary care (Finland). Based on prescriptions, ADHD prevalence ranged from 0.1 (Emilia Romagna) to 9.9 (Haute Garonne). ASD prevalence in specialist settings ranged from 5.6 (Wales) to 9.7 (Finland), and in primary care from 1.0 (Finland) to 2.0 (Wales). Prevalence of ADHD and ASD was greater among children with longer follow-up. In Finland and Wales, 1.7% and 19.4% of children were diagnosed with ASD in primary care only respectively. The male:female ratio was 3-4:1. Whilst there was considerable geographical variation in the length of follow-up available, and prevalence of ADHD and ASD, specialist diagnoses recorded in healthcare data were key to identifying children with these disorders. These data sources can be complemented by using primary care diagnoses and prescription data to identify affected children more comprehensively.
Authors
- Anna‐Belle Beau (ORCID: https://orcid.org/0000-0003-4631-100X)
- Maria Loane (ORCID: https://orcid.org/0000-0002-1206-3637)
- Joanne Given (ORCID: https://orcid.org/0000-0003-4921-1944)
- Aurora Puccini
- Olga Paoletti (ORCID: https://orcid.org/0009-0009-0434-8745)
- Christine Damase‐Michel (ORCID: https://orcid.org/0000-0001-5018-0108)
- Joan K. Morris (ORCID: https://orcid.org/0000-0002-7164-612X)
- F Coste (ORCID: https://orcid.org/0000-0001-7109-388X)
- Marco Manfrini (ORCID: https://orcid.org/0000-0003-3154-9269)
- Hywel Evans (ORCID: https://orcid.org/0000-0001-6745-4187)
- Rebecca Bromley (ORCID: https://orcid.org/0000-0003-4008-0917)
- Claudia Bartolini (ORCID: https://orcid.org/0000-0001-8630-4598)
- Maarit K. Leinonen (ORCID: https://orcid.org/0000-0002-7631-4749)
- Hedvig Nordeng (ORCID: https://orcid.org/0000-0001-6361-2918)
- Sue Jordan (ORCID: https://orcid.org/0000-0002-5691-2987)
- Elisa Ballardini (ORCID: https://orcid.org/0000-0002-8813-1835)
- Visa Martikainen
- Anthony Caillet
- Amanda J. Neville
- Alex Coldea
Institutions
- University of Helsinki (FI)
- Université Toulouse III - Paul Sabatier (FR)
- University of Ulster (GB)
- Inserm (FR)
- St George's, University of London (GB)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- University of Oslo (NO)
- University of Ferrara (IT)
- Manchester Academic Health Science Centre (GB)
- Helsinki University Hospital (FI)
- University of Manchester (GB)
- Sanofi (France) (FR)
- Swansea University (GB)
- Finnish Institute for Health and Welfare (FI)
- Agenzia Regionale di Sanità della Toscana (IT)
- Royal Manchester Children's Hospital (GB)
- Regione Emilia-Romagna
Publication Details
- Journal
- Journal of Autism and Developmental Disorders
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1007/s10803-025-06997-4
- Citations
- 1
- Primary Topic
- Autism Spectrum Disorder Research
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- European Federation of Pharmaceutical Industries and Associations
- Innovative Medicines Initiative